{"title":"人乳头瘤病毒94型相关扁平疣在托法替尼治疗期间反复发生：一例报告和回顾","authors":"Nobuhiro Takahashi, Tomomichi Shimizu, Akio Kondoh, Kazushi Anzawa, Akira Shimizu, Tomotaka Mabuchi","doi":"10.1111/1346-8138.17814","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Flat warts are typically caused by human papillomavirus (HPV) type 3 or 10, while HPV 94 is rarely detected. The warts on a 76-year-old Japanese male with rheumatoid arthritis (RA) appeared after 8 months of tofacitinib treatment but disappeared upon switching to filgotinib. However, the warts reappeared when tofacitinib was resumed. Histopathological and DNA sequencing confirmed HPV 94. While Janus kinase (JAK) inhibitors are known to increase viral reactivation risks, including herpes zoster, this case highlights a possible link between tofacitinib and HPV 94-related flat warts. Tofacitinib may suppress IL-15 signaling, weakening antiviral immunity and promoting HPV reactivation. Although HPV-specific immunity in RA- and tofacitinib-treated patients remains unclear, this case provides new insights into JAK inhibitor–related viral reactivation, particularly for HPV 94–associated flat warts.</p>\n </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 8","pages":"1317-1320"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Human Papilloma Virus Type 94–Associated Flat Warts Developing Repeatedly During Tofacitinib Treatment: A Case Report and Review\",\"authors\":\"Nobuhiro Takahashi, Tomomichi Shimizu, Akio Kondoh, Kazushi Anzawa, Akira Shimizu, Tomotaka Mabuchi\",\"doi\":\"10.1111/1346-8138.17814\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Flat warts are typically caused by human papillomavirus (HPV) type 3 or 10, while HPV 94 is rarely detected. The warts on a 76-year-old Japanese male with rheumatoid arthritis (RA) appeared after 8 months of tofacitinib treatment but disappeared upon switching to filgotinib. However, the warts reappeared when tofacitinib was resumed. Histopathological and DNA sequencing confirmed HPV 94. While Janus kinase (JAK) inhibitors are known to increase viral reactivation risks, including herpes zoster, this case highlights a possible link between tofacitinib and HPV 94-related flat warts. Tofacitinib may suppress IL-15 signaling, weakening antiviral immunity and promoting HPV reactivation. Although HPV-specific immunity in RA- and tofacitinib-treated patients remains unclear, this case provides new insights into JAK inhibitor–related viral reactivation, particularly for HPV 94–associated flat warts.</p>\\n </div>\",\"PeriodicalId\":54848,\"journal\":{\"name\":\"Journal of Dermatology\",\"volume\":\"52 8\",\"pages\":\"1317-1320\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17814\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17814","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Human Papilloma Virus Type 94–Associated Flat Warts Developing Repeatedly During Tofacitinib Treatment: A Case Report and Review
Flat warts are typically caused by human papillomavirus (HPV) type 3 or 10, while HPV 94 is rarely detected. The warts on a 76-year-old Japanese male with rheumatoid arthritis (RA) appeared after 8 months of tofacitinib treatment but disappeared upon switching to filgotinib. However, the warts reappeared when tofacitinib was resumed. Histopathological and DNA sequencing confirmed HPV 94. While Janus kinase (JAK) inhibitors are known to increase viral reactivation risks, including herpes zoster, this case highlights a possible link between tofacitinib and HPV 94-related flat warts. Tofacitinib may suppress IL-15 signaling, weakening antiviral immunity and promoting HPV reactivation. Although HPV-specific immunity in RA- and tofacitinib-treated patients remains unclear, this case provides new insights into JAK inhibitor–related viral reactivation, particularly for HPV 94–associated flat warts.
期刊介绍：
The Journal of Dermatology is the official peer-reviewed publication of the Japanese Dermatological Association and the Asian Dermatological Association. The journal aims to provide a forum for the exchange of information about new and significant research in dermatology and to promote the discipline of dermatology in Japan and throughout the world. Research articles are supplemented by reviews, theoretical articles, special features, commentaries, book reviews and proceedings of workshops and conferences.
Preliminary or short reports and letters to the editor of two printed pages or less will be published as soon as possible. Papers in all fields of dermatology will be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
